Introduction
Many men with non-clinically significant PCa (N-CSPCa) will not progress
to become symptomatic within their lifetime. If we can predict
clinically significant PCa (CSPCa), we can prevent patients from
unnecessary biopsies, overdiagnoses, and overtreatment. The purpose of
this study was to determine whether PSAD and f/t PSA can predict CSPCa
(Gleason ≥ 7) in patients diagnosed with prostate cancer on biopsy with
a PSA level of 2.5-10 ng/ml or not.